U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H11N7
Molecular Weight 253.2631
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIAMTERENE

SMILES

c1ccc(cc1)-c2c(=N)nc3-c(c(N)[nH]c(=N)[nH]3)n2

InChI

InChIKey=FNYLWPVRPXGIIP-UHFFFAOYSA-N
InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/triamterene.html

Triamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.Triamterene is used for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism. Triamterene is maeketed under the trade name Dyrenium.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DYRENIUM

Approved Use

Edema: For the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism.

Launch Date

-1.70294395E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
46.4 ng/mL
37.5 mg 1 times / day multiple, oral
dose: 37.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
125.1 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
44.77 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
148.7 ng × h/mL
37.5 mg 1 times / day multiple, oral
dose: 37.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
488.4 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
190.69 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.75 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
unknown
TRIAMTERENE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
33%
37.5 mg 1 times / day multiple, oral
dose: 37.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
38.7%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAMTERENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 2 times / day multiple, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Co-administed with::
hydrochlorothiazide(50 mg twice daily; 28 days)
Sources:
unhealthy, 54 ± 3 years
n = 9
Health Status: unhealthy
Condition: hypokalemia
Age Group: 54 ± 3 years
Population Size: 9
Sources:
Other AEs: Kidney failure...
Other AEs:
Kidney failure (acute)
Sources:
37.5 mg 1 times / day single, oral
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg)
Sources:
unhealthy
Disc. AE: Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia
Sources:
AEs

AEs

AESignificanceDosePopulation
Kidney failure acute
100 mg 2 times / day multiple, oral
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Co-administed with::
hydrochlorothiazide(50 mg twice daily; 28 days)
Sources:
unhealthy, 54 ± 3 years
n = 9
Health Status: unhealthy
Condition: hypokalemia
Age Group: 54 ± 3 years
Population Size: 9
Sources:
Hyperkalemia Disc. AE
37.5 mg 1 times / day single, oral
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg)
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Irreversible renal failure associated with triamterene.
1991
Micellar electrokinetic capillary chromatography analysis of diuretics in pharmaceutical formulations.
2002 May 16
Drug-induced urinary calculi.
2003 Fall
[Determination of five components in compound hypotensive tablet by HPLC].
2004 Aug
Application of PLS regression to fluorimetric data for the determination of furosemide and triamterene in pharmaceutical preparations and triamterene in urine.
2004 Feb 6
The G-tolerance after pharmacological hypohydration.
2004 Jul
[Circadian rhythm of the renin-angiotensin-aldosterone system: a summary of our research studies].
2004 Jul-Aug
Use of the TriSpan coil to facilitate the transcatheter occlusion of pulmonary arteriovenous malformation.
2004 Nov-Dec
Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
2005 Aug
[Capillary electrophoresis with end-column electrochemical detection for hydrochlorothiazide and triamterene diuretics].
2005 Jan
[A case of Gitelman's syndrome presenting with severe hypocalcaemia and hypokalemic periodic paralysis].
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Capillary electrophoretic determination of triamterene, methotrexate, and creatinine in human urine.
2005 May
Multicommuted flow-through fluorescence optosensor for determination of furosemide and triamterene.
2005 Nov
Drug-induced megaloblastic anemia.
2005 Oct
[Differential diagnosis of a macrocytic, hyperchromic anemia following alcohol abuse and simultaneous therapy with triamterene and cotrimoxazole].
2005 Sep 23
Design, synthesis and diuretic activity of some novel 2,4-diamino-6-aryl-7-arylaminopyrimido [4,5-d]pyrimidin-5(6H)-ones.
2006
[Drug-induced renal calculi].
2006 Apr
High-speed gas chromatography in doping control: fast-GC and fast-GC/MS determination of beta-adrenoceptor ligands and diuretics.
2006 Dec
Fast gas chromatographic/mass spectrometric determination of diuretics and masking agents in human urine: Development and validation of a productive screening protocol for antidoping analysis.
2006 Dec 1
[Liddle syndrome: Pathogenesis, pathophysiology, and therapy].
2006 Feb
[Diuretic therapy in heart failure].
2006 Jan-Feb
Potassium-sparing diuretics.
2006 Jul 11-17
[Influence of diuretics on occupationally important qualities of engine drivers].
2007
Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis.
2007
Periprocedural morbidity and mortality by endovascular treatment of cerebral aneurysms with GDC: a retrospective 12-year experience of a single center.
2007 Apr
Stereoselective syntheses of the 2-Isopropenyl-2,3-dihydrobenzofuran nucleus: potential chiral building blocks for the syntheses of tremetone, hydroxytremetone, and rotenone.
2007 Apr 13
Fast quantitative determination of diuretic drugs in tablets and human urine by microchip electrophoresis with native fluorescence detection.
2007 Aug
Naturalised Vitis rootstocks in Europe and consequences to native wild grapevine.
2007 Jun 13
Update of diuretics in the treatment of hypertension.
2007 Mar-Apr
A study of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown.
2007 Sep
Determination of norfloxacin in rat liver perfusate using capillary electrophoresis with laser-induced fluorescence detection.
2007 Sep 1
Determination of losartan and triamterene in pharmaceutical compounds and urine using cathodic adsorptive stripping voltammetry.
2008
Practical aspects in the management of hypokalemic periodic paralysis.
2008 Apr 21
Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents.
2008 Aug 25
Evaluation of a neck-bridge device to assist endovascular treatment of wide-neck aneurysms of the anterior circulation.
2008 Jan
How long does it take to coil an intracranial aneurysm?
2008 Jan
Acute bilateral simultaneous angle closure glaucoma after topiramate administration: a case report.
2008 Jan 8
Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes.
2008 Jul
Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
2008 Jun
Drug-induced crystal nephropathy: an update.
2008 Mar
Simultaneous determination of triamterene and hydrochlorothiazide in tablets using derivative spectrophotometry.
2008 May-Jun
The prince and the pauper. A tale of anticancer targeted agents.
2008 Oct 23
Determination of diuretics in human urine by hollow fiber-based liquid-liquid-liquid microextraction coupled to high performance liquid chromatography.
2008 Sep
Responses to diuretic treatment in gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1.
2009
Update on the treatment of ocular toxoplasmosis.
2009
Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism.
2009 Apr 7
Consensus guidelines for oral dosing of primarily renally cleared medications in older adults.
2009 Feb
[Asynchronous lumbar synovial cysts after surgical resection: a case report].
2009 Mar-Apr
Heritable forms of hypertension.
2009 Oct
Patents

Sample Use Guides

In Vivo Use Guide
Edema: Oral: 100 to 300 mg daily in 1 to 2 divided doses; maximum dose: 300 mg daily
Route of Administration: Oral
In Vitro Use Guide
Triamterene in the concentration range from 8X10(-13) mol/l to 8X10(-3) mol/l exerted a dose-dependent inhibitory effect of the rat kidney plasma membrane Na-K-Mg-ATPase and Na-K-ATPase activities--estimated IC50 values lay at about 8X10(-3) mol/l and 8X10(-7) mol/l, respectively.
Name Type Language
TRIAMTERENE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
DYAZIDE COMPONENT TRIAMTERENE
Common Name English
SK&F 8542
Code English
TRIAMTERENE [USP MONOGRAPH]
Common Name English
TRIAMTERENE [WHO-DD]
Common Name English
TRIAMTERENE [USP]
Common Name English
2,4,7-PTERIDINETRIAMINE, 6-PHENYL-
Systematic Name English
TRIAMTERENE COMPONENT OF DYAZIDE
Common Name English
NSC-639359
Code English
TRIAMTERENE [ORANGE BOOK]
Common Name English
TRIAMTERENE [USAN]
Common Name English
TRIAMTERENE [IARC]
Common Name English
TRIAMTERENE [USP-RS]
Common Name English
TRIAMTERENE [MART.]
Common Name English
TRIAMTERENE [INN]
Common Name English
SK-8542
Code English
MAXZIDE COMPONENT TRIAMTERENE
Common Name English
2,4,7-TRIAMINO-6-PHENYLPTERIDINE
Systematic Name English
NSC-77625
Code English
TRIAMTERENE [HSDB]
Common Name English
SK&F-8542
Code English
TRIAMTERENE [MI]
Common Name English
TRIAMTERENE [VANDF]
Common Name English
TRIAMTERENE COMPONENT OF MAXZIDE
Common Name English
TRIAMTERENE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC C03DB02
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
NDF-RT N0000175418
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
NCI_THESAURUS C49186
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
LIVERTOX 995
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
NDF-RT N0000175359
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
WHO-VATC QC03DB02
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
NDF-RT N0000008859
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL585
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
CAS
396-01-0
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
PUBCHEM
5546
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
DRUG BANK
DB00384
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
LACTMED
Triamterene
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
WIKIPEDIA
TRIAMTERENE
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
NCI_THESAURUS
C29519
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
RXCUI
10763
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY RxNorm
HSDB
3405
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
EVMPD
SUB11256MIG
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
DRUG CENTRAL
2728
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
EPA CompTox
396-01-0
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
MESH
D014223
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
MERCK INDEX
M11030
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1680007
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY USP-RS
IUPHAR
4329
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
INN
1266
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-904-3
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY
FDA UNII
WS821Z52LQ
Created by admin on Fri Jun 25 20:53:49 UTC 2021 , Edited by admin on Fri Jun 25 20:53:49 UTC 2021
PRIMARY